Effects of single doses of Stalevo [levodopa/carbidopa/entacapone] 200 and levodopa/carbidopa 200/50mg on striatal 11C-raclopride binding potential in Parkinson's disease patients with wearing-off symptoms; an open, randomised, active-controlled,two-period crossover study
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2016
At a glance
- Drugs Levodopa/carbidopa/entacapone (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Orion
- 09 Oct 2009 Planned end date changed from 1 Jul 2008 to 1 May 2008 as reported by ClinicalTrials.gov.
- 09 Oct 2009 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 05 Dec 2007 New trial record.